The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 08, 2019

Filed:

Dec. 28, 2015
Applicants:

Nippon Chemiphar Co., Ltd., Tokyo, JP;

J-pharma Co., Ltd., Kanagawa, JP;

Dethree Res. Lab. Inc., Ibaraki, JP;

Inventors:

Tsuyoshi Endo, Misato, JP;

Kunio Kobayashi, Misato, JP;

Hiroto Tanaka, Misato, JP;

Daisuke Saito, Misato, JP;

Masuharu Hirano, Misato, JP;

Hitoshi Endou, Kanagawa, JP;

Naohiko Anzai, Tokyo, JP;

Assignees:

Nippon Chemiphar Co., Ltd., Tokyo, JP;

J-Pharma Co., Ltd., Kanagawa, JP;

DeThree Res. Lab. Inc., Ibaraki, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 275/04 (2006.01); C07D 411/04 (2006.01); C07C 255/54 (2006.01); C07D 215/20 (2006.01); C07D 215/36 (2006.01); C07C 321/24 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 263/54 (2006.01); C07D 209/08 (2006.01); C07D 277/62 (2006.01); C07D 285/14 (2006.01); C07D 213/30 (2006.01); A61K 31/277 (2006.01); A61K 31/404 (2006.01); A61K 31/423 (2006.01); A61K 31/428 (2006.01); A61K 31/433 (2006.01); A61K 31/437 (2006.01); A61K 31/4406 (2006.01); A61K 31/47 (2006.01); A61K 31/33 (2006.01);
U.S. Cl.
CPC ...
C07D 275/04 (2013.01); A61K 31/277 (2013.01); A61K 31/33 (2013.01); A61K 31/404 (2013.01); A61K 31/423 (2013.01); A61K 31/428 (2013.01); A61K 31/433 (2013.01); A61K 31/437 (2013.01); A61K 31/4406 (2013.01); A61K 31/47 (2013.01); C07C 255/54 (2013.01); C07C 321/24 (2013.01); C07D 209/08 (2013.01); C07D 213/30 (2013.01); C07D 215/20 (2013.01); C07D 215/36 (2013.01); C07D 263/54 (2013.01); C07D 277/62 (2013.01); C07D 285/14 (2013.01); C07D 411/04 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01);
Abstract

Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia. (In the Formula (III), R, R, R, and Rrepresent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, or a cyano group, Rand Rform a benzene ring or a 5-membered heteroaryl ring containing 1 to 3 heteroatoms, as a ring constituent element, selected from nitrogen atoms, oxygen atoms, and sulfur atoms together with two carbon atoms to which Rand Rare bonded, Rand Rform a benzene ring together with two carbon atoms to which Rand Rare bonded or represent any of the groups represented by Rdescribed above, Wrepresents CRor N, and where, Rrepresents any of the groups represented by R, Xrepresents an oxygen atom or a sulfur atom, Yrepresents an alkylene chain having 1 to 8 carbon atoms, and where, the alkylene chain may be substituted with an alkyl group having 1 to 8 carbon atoms and the alkylene chain may be a linear or branched alkylene chain, the branched alkylene chain may have a 3- to 7-membered ring formed by side chains bonded to carbon atoms which are the same as or different from each other, together with the carbon atoms to which the side chains are bonded and may have a double bond in the middle thereof, and Zrepresents COH).


Find Patent Forward Citations

Loading…